10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2021-08-16 (Q2 2021) | Holdings: 120 | Value: $22.8B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seagen Inc. | 32.79% | $7.5B | +18.49% | +10.09% | |||
| BGNE - BeiGene, Ltd. | 17.59% | $4.0B | -10.38% | +38.72% | -34.38% | ||
| INCY - Incyte Corporation | 11.83% | $2.7B | -11.64% | -11.69% | +0.31% | ||
| KOD - Kodiak Sciences Inc. | Add 2% ($24.0M) | 5.77% | $1.3B | -95.91% | +22.72% | -86.07% | |
| ACAD - ACADIA Pharmaceuticals Inc. | 4.49% | $1.0B | +29.71% | +17.14% | +2.59% | ||
| BMRN - BioMarin Pharmaceutical Inc. | 2.78% | $633.3M | -22.36% | +7.96% | +26.81% | ||
| ASND - Ascendis Pharma A/S | 2.05% | $465.7M | +40.54% | +33.74% | -16.47% | ||
| NVTA - Invitae Corporation | Reduce 35% $(185.5M) | 1.52% | $345.7M | -15.73% | -83.07% | ||
| ARGX - argenx SE | 1.48% | $337.1M | +89.26% | -0.83% | +26.32% | ||
| PRLD - Prelude Therapeutics Incorporated | 1.27% | $289.8M | -97.21% | -50.60% | -74.46% | ||
| IGMS - IGM Biosciences, Inc. | 1.15% | $262.6M | -98.21% | -13.38% | -65.70% | ||
| ABCL - AbCellera Biologics Inc. | 1.01% | $229.9M | -87.88% | -11.04% | -21.91% | ||
| MRTX - Mirati Therapeutics, Inc. | 1.00% | $227.7M | +1.59% | -41.16% | |||
| BCRX - BioCryst Pharmaceuticals, Inc. | 0.88% | $201.0M | -27.80% | -19.34% | -4.30% | ||
| MDGL - Madrigal Pharmaceuticals, Inc. | 0.64% | $146.0M | +234.62% | +5.71% | -9.37% | ||
| APLS - Apellis Pharmaceuticals, Inc. | Add 36% ($37.8M) | 0.63% | $143.6M | -69.71% | -19.26% | +22.88% | |
| HRTX - Heron Therapeutics, Inc. | Add 36% ($33.2M) | 0.55% | $126.2M | -82.11% | +2.47% | -51.38% | |
| AMRN - Amarin Corporation plc | 0.51% | $115.9M | -89.07% | -22.08% | -69.25% | ||
| GBT - Global Blood Therapeutics, Inc. | 0.49% | $112.7M | +24.96% | +153.93% | |||
| PACB - Pacific Biosciences of California, Inc. | 0.49% | $112.0M | -96.56% | -3.39% | -72.82% | ||
| IMCR - Immunocore Holdings plc | 0.43% | $98.4M | +25.90% | +35.47% | +83.18% | ||
| KYMR - Kymera Therapeutics, Inc. | 0.42% | $95.0M | -40.72% | +25.18% | -42.48% | ||
| VSTM - Verastem, Inc. | Add 26% ($18.2M) | 0.38% | $87.5M | -76.62% | +17.54% | -51.49% | |
| VERV - Verve Therapeutics, Inc. | New Purchase | 0.37% | $85.3M | -92.53% | -30.52% | -39.37% | |
| TLIS - Talis Biomedical Corporation | 0.37% | $83.5M | -98.68% | -41.53% | -87.03% | ||
| CERS - Cerus Corporation | 0.36% | $81.0M | -78.29% | +24.62% | -16.58% | ||
| DBVT - DBV Technologies S.A. | 0.35% | $79.8M | -82.78% | -37.53% | -47.22% | ||
| RYTM - Rhythm Pharmaceuticals, Inc. | Add 11% ($7.5M) | 0.33% | $75.6M | +391.82% | -3.77% | +93.74% | |
| TIL - Instil Bio, Inc. | 0.33% | $75.2M | -91.63% | +33.48% | -57.08% | ||
| LEGN - Legend Biotech Corporation | New Purchase | 0.30% | $68.3M | -24.35% | +45.62% | +17.59% | |
| NBIX - Neurocrine Biosciences, Inc. | 0.29% | $65.9M | +36.84% | -0.33% | +16.73% | ||
| NRIX - Nurix Therapeutics, Inc. | 0.29% | $65.1M | -63.70% | +15.54% | -47.30% | ||
| INSM - Insmed Incorporated | 0.27% | $61.4M | +209.09% | +34.53% | +14.23% | ||
| ALLK - Allakos Inc. | 0.26% | $60.0M | +3.44% | -95.65% | |||
| ZYME - Zymeworks Inc. | 0.26% | $59.3M | -63.73% | -37.86% | -79.72% | ||
| HZNP - Horizon Therapeutics Public Ltd Co | 0.25% | $56.1M | +2.19% | -41.63% | |||
| FMTX - Forma Therapeutics Holdings, Inc. | 0.22% | $50.4M | -13.63% | -48.44% | |||
| IMTX - Immatics N.V. | Add 7% ($3.4M) | 0.22% | $49.7M | -54.09% | +4.34% | -3.92% | |
| N/A - Insmed Incorporated | New Purchase | 0.19% | $44.1M | ||||
| MRUS - Merus N.V. | 0.19% | $42.9M | +204.89% | +55.14% | +30.51% | ||
| RARE - Ultragenyx Pharmaceutical Inc. | 0.19% | $42.4M | -60.56% | -10.19% | -45.24% | ||
| ADAP - Adaptimmune Therapeutics plc | 0.18% | $41.9M | -92.59% | +7.09% | -47.09% | ||
| KRYS - Krystal Biotech, Inc. | Reduce 20% $(10.4M) | 0.18% | $41.3M | +136.77% | -7.73% | +38.97% | |
| KNSA - Kiniksa Pharmaceuticals, Ltd. | 0.17% | $39.0M | +136.27% | +11.31% | +3.45% | ||
| N/A - Sarepta Therapeutics, Inc. | New Purchase | 0.17% | $38.5M | ||||
| FLGT - Fulgent Genetics, Inc. | 0.16% | $37.0M | -78.25% | +3.22% | -49.54% | ||
| AXSM - Axsome Therapeutics, Inc. | New Purchase | 0.16% | $36.4M | +401.48% | +64.76% | +105.67% | |
| NLTX - Neoleukin Therapeutics, Inc. | 0.15% | $35.3M | |||||
| BCAB - BioAtla, Inc. | 0.15% | $35.0M | -98.97% | -28.60% | -74.27% | ||
| ADCT - ADC Therapeutics SA | New Purchase | 0.15% | $34.5M | -88.18% | -4.40% | -66.12% | |
| ACHL - Achilles Therapeutics plc | Reduce 100% | 0.00% | $0.00 | ||||
| ALXN - Alexion Pharmaceuticals, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| ALT - Altimmune, Inc. | Reduce 100% | 0.00% | $0.00 | -25.61% | -6.60% | +49.22% | |
| BCEL - Atreca, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| DSGN - Design Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| PTGX - Protagonist Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||